P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY
H. Einsele,
P. Moreau,
M. Delforge,
N. W. van de Donk,
F. Ghilotti,
J. Diels,
A. Elsada,
V. Strulev,
L. Pei,
R. Kobos,
J. Smit,
M. Slavcev,
K. Weisel,
M.-V. Mateos
Affiliations
H. Einsele
1 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Germany
P. Moreau
2 Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France
M. Delforge
3 University of Leuven, Leuven, Belgium
N. W. van de Donk
4 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
F. Ghilotti
5 Janssen-Cilag SpA, Cologno Monzese, United States of America
J. Diels
6 Janssen Pharmaceutica NV, Beerse, Belgium
A. Elsada
7 Janssen-Cilag, High Wycombe, Buckinghamshire, United Kingdom
V. Strulev
6 Janssen Pharmaceutica NV, Beerse, Belgium
L. Pei
8 Janssen Research & Development, Raritan
R. Kobos
8 Janssen Research & Development, Raritan
J. Smit
9 Janssen Research & Development, Spring House
M. Slavcev
10 Janssen Global Services, LLC, Raritan, United States of America
K. Weisel
11 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
M.-V. Mateos
12 University Hospital of Salamanca/IBSAL, CIC, Salamanca, Spain
